The Opioid Crisis: Purdue Pharma and the Sackler Family
How Purdue Pharma marketed OxyContin with fraudulent safety claims while the Sackler family extracted billions
The Marketing of OxyContin
Purdue Pharma introduced OxyContin in 1996, marketing it as a breakthrough pain medication with a low risk of addiction. The company’s central claim — that OxyContin’s time-release formulation made it less addictive than other opioids — was not supported by clinical evidence. Internal documents later revealed in litigation showed that Purdue was aware of OxyContin’s addictive potential before it launched.
Purdue deployed an aggressive sales strategy. The company’s sales force more than doubled between 1996 and 2001. Representatives were trained to tell physicians that the risk of addiction from OxyContin was “less than one percent” — a claim derived from a misrepresentation of a brief 1980 letter to the editor in the New England Journal of Medicine that had nothing to do with OxyContin or time-release opioids. Purdue spent over $200 million annually on marketing at the program’s peak, including branded promotional items, all-expenses-paid conferences, and bonus programs that rewarded representatives for increasing prescriptions.
The Sackler Family’s Extraction
The Sackler family, which privately owned Purdue Pharma, extracted approximately $11 billion from the company between 2008 and 2018, even as litigation and investigations mounted. Internal records showed that family members were directly involved in marketing decisions and were aware of the addiction crisis. Richard Sackler, then president of Purdue, wrote in a 1997 email at OxyContin’s launch: “The launch of OxyContin Tablets will be followed by a blizzard of prescriptions that will bury the competition.”
Criminal and Civil Accountability
In 2007, Purdue Pharma and three executives pleaded guilty to federal charges of misbranding OxyContin, paying $634.5 million in fines. The executives received no prison time. The company continued marketing OxyContin with modified claims.
In 2020, Purdue Pharma pleaded guilty to additional federal charges, including conspiracy to defraud the United States and violating anti-kickback statutes. The company agreed to an $8.3 billion settlement, though most of that amount was uncollectable because Purdue had already entered bankruptcy.
The Supreme Court and the Sackler Shield
In June 2024, the U.S. Supreme Court ruled 5-4 in Harrington v. Purdue Pharma that the bankruptcy plan granting the Sackler family legal immunity from future opioid-related lawsuits in exchange for contributing approximately $6 billion to the settlement was impermissible. The Court held that the Bankruptcy Code does not authorize the release of third-party claims against non-debtors without the claimants’ consent.
Following the Supreme Court ruling, a revised settlement was negotiated. In 2025, a new agreement valued at approximately $7.4 billion was reached, with the Sackler family contributing a larger share but still receiving modified liability protections. The settlement directs funds toward opioid abatement programs across all 50 states.
The Human Cost
The opioid crisis has killed more than 500,000 Americans since 1999. OxyContin was the gateway drug for many who later transitioned to heroin and illicit fentanyl. The CDC estimates that opioids were involved in approximately 82,000 overdose deaths in 2022 alone.
Research Verdict
| Assessment | CONFIRMED |
| Confidence | High |
| Summary | Purdue Pharma knowingly marketed OxyContin with fraudulent addiction-risk claims while the Sackler family extracted billions in profits as the opioid crisis killed hundreds of thousands |